Molecular imaging is a rapidly emerging biomedical research discipline, which may be defined as the visual representation, characterization and quantification of biological processes at both the cellular and subcellular levels within a living organism. The in vivo monitoring of specific molecular and cellular processes, for example gene expression; multiple simultaneous molecular events; progression or regression of cancer; and drug and gene therapy are the major goals of this evolving technology. There are certain prerequisites for visualizing specific molecules or molecular mechanisms in vivo. The major ones are: (1) the availability of stable, nontoxic and high-affinity probes; (2) the ability of these probes to overcome biological delivery barriers, such as the bloodbrain barrier; (3) the use of amplification strategies to increase the signal to background ratio; and (4) the availability of fast and high-resolution imaging techniques. 1 Imaging of gene expression is increasingly essential for cancer diagnosis, prediction of tumor response to available therapies and monitoring response to therapy. There has been an explosion in the field of gene expression imaging with the availability of a variety of cloning vectors and animal models, the ease of recombinant DNA technology and the importance to preclinical evaluation and clinical applications. Different classes of marker genes (encoding proteins, enzymes or cell-surface receptors) that can be detected with different imaging modalities have been described. 2, 3 The various existing imaging technologies differ in a variety of aspects: spatial and temporal resolution, depth of penetration, energy expended for image generation, availability of the injectable probes and the detection threshold of probes for a given technology. Table 1 outlines some of the general characteristics of the available imaging modalities and also serves as a guide for biologists in choosing appropriate molecular imaging modalities for answering a particular biological question. Various methods of gene therapy have been used. The majority of the gene therapy protocols have used viral vectors which provide a way to monitor biological functions; replace, correct, express or block expression of defective or target genes; tag cells for fate determinations; and change the physiological state of specific cell populations. The available vectors differ in their suitability for different applications, depending on such factors as size of transgene, route of delivery, tropism, duration/regulation of gene expression, and possible side effects (Table 2) . Although gene therapy has met with limited success to date, it remains probable that many diseases will be successfully treated in the future with the delivery of one or more transgenes to target tissues, combined with conventional therapies. A major limitation in applying gene therapy is the difficulty in achieving controlled and efficient delivery of genes via viral and non-viral vectors, and recently via stem cells, which home to damaged areas. Various existing molecular imaging technologies (Table 1) offer a platform to address issues like in vivo vector biodistribution, monitoring of the location, magnitude and the duration of vector-mediated gene expression, and tracking the migration of stem cells. Molecular imaging of reporters for specific genes could play a crucial role in optimizing gene therapy by quantitatively imaging reporter gene expression and tumor volumes.
Nuclear imaging
Radionuclide imaging (positron emission tomography (PET) and single photon emission tomography (SPECT)) enables the assessment of the intensity and regional/ spatial distribution of gene expression in vivo. Nuclear imaging techniques are unique in providing the higher sensitivity with moderate spatial resolution required to evaluate gene expression via its protein product, which may be an enzyme leading to specific trapping of radiolabeled marker substrate 4, 5 or a receptor leading to binding of radiolabeled receptor ligands. 6 Both 
PET
PET constitutes a major advance in the assessment and follow-up of patients with cancer. PET is used to detect decaying nuclides such as 11 C, 18 F, 15 O, 124 I and images the distribution in vivo of trace quantities of positronemitting molecular probe administered. Positrons emitted from the probe travel a few millimeters in tissue before being annihilated by collision with an electron, resulting in a pair of high-energy photons. These photon pairs are detected by the PET scanner and are then used to reconstruct volumetric images of the positron-emitting probe. 7 Positron-emitting radionucleotides are primarily used to tag small molecules that are recognized by enzymes or bind to receptors or membrane transporters. [8] [9] [10] In principle, PET directly measures the expression of a PET reporter protein and thereby gives an indirect evaluation of the expression of a therapeutic gene of interest. Depending on the radionucleotide used, various molecular processes can be visualized by PET, most of them related to cell proliferation within tumors. 11 The ability of PET to image gene expression quantitatively, combined with the ease of translation of techniques developed for small-animal PET imaging to the clinic, has been of clear benefit in gene therapy trials. For example, in patients with recurrent glioblastomas, PET allowed (i) identification of viable and biologically active tumor tissue; (ii) targeted vector delivery; (iii) evaluation of transduction efficiency of the herpes simplex virus type 1 thymidine kinase gene (HSV-1-tk); and (iv) evaluation of therapeutic efficiency of the activation of the prodrug, ganciclovir, to a toxic nucleoside analog. 12 The thymidine kinase (TK) enzyme acts to convert this relatively nontoxic substrate into compounds selectively toxic to dividing cells, resulting in tumor cell death. PET 
, which are specifically phosphorylated by the HSV-1-TK enzyme and trapped within the cell, have been successfully used for the noninvasive localization of retroviral, 5 herpes viral 13, 14 (Figures 1,2 ) and adenoviral 15 vector-mediated HSV-1-TK expression in animal models.
The sodium/iodide symporter (NIS) is a membrane glycoprotein that uses the transmembrane sodium gradient maintained by the sodium/potassium ATPase to cotransport iodine and sodium into thyroid cells. 16 The gene encoding NIS has been used as a suicide treatment of nonthyroid tumors, like prostate tumor xenografts, in animal models. NIS transport is decreased in thyroid malignancies as compared to normal thyroid tissue, thus enabling thyroid cancer detection as sites of enhanced accumulation of radiotracer. The injection of a recombinant adenovirus encoding the rat NIS gene into tumors triggered significant 131 I uptake by the tumors and produced a significant reduction in their volume, thus outlining the potential of this novel cancer gene therapy approach for targeted radiotherapy. 17, 18 However, application of NIS as a suicide protein has been limited by lack of retention of radioactivity in nonthyroid tissues. 19 Recently, this limitation has been overcome by coexpression of both NIS and thyroperoxidase (TPO), the latter of which catalyzes iodination of proteins and subsequent iodide retention within thyroid cells, thus resulting in enhanced tumor cell apoptosis consequent to increased radioiodide uptake and retention. 20 PET technology has been miniaturized for imaging small animals. MicroPET is a noninvasive system that allows serial and longitudinal evaluation to be performed on the same living animal, thus enabling tracking of a single animal over time and monitoring effects of interventions on disease progression and outcome. MicroPET imaging in mice, with high spatial resolution up to 1-2 mm full-width at half-maximum (FWHM), was used to study expression of wild-type dopamine type-2 receptor (D 2 R) and mutant dopamine type-2 receptor (mD 2 R) by using a specific D 2 receptor-binding compound [ . Genes for mD 2 R, which is incapable of signal transduction, and a mutant form of HSV-1-TK (HSV1-sr39tk) with higher substrate affinity were placed together under an inducible bidirectional tetracycline-regulated promoter in a vector, such that doxycycline coinitiates their transcription. 21, 22 The expression of both genes was quantified and colocalized in the same animal by PET imaging, revealing the potential of PET to monitor multiple coexpressed genes. 23, 24 Recently expression of the HSV1-sr39tk reporter gene, delivered by a replication defective adenovirus vector, was noninvasively and repetitively monitored at intervals over 3 months by microPET using 9-[(4-[(18)F]fluoro-3-hydroxymethylbutyl)guanine as probe. 22 MicroPET has also been used to monitor correlated expression of two coding regions of a bicistronic transcription unit. An adenovirus vector was constructed containing the D 2 R gene followed by a virus internal ribosomal entry site (IRES) derived from picornavirus and a modified HSV1-tk gene. Following intravenous injection of this vector into mice, coordinated D 2 R and HSV1-sr39tk gene expression was demonstrated in the liver with repeated microPET. 22 This technique can be applied both in studies of gene therapy and gene expression in transgenic animals.
In principle, proportional coexpression of two genes can be achieved by two coordinately acting promoters, 13 by gene fusion and by certain translational linkers, such as the IRES, 14, 24 or self-processing peptides (eg foot-andmouth disease virus 2A) and proteins with proteolytic cleavable sites (eg fusagen). 25 Two examples of proportionally coexpressed imaging genes are demonstrated in and an additional IRES to link the cd gene. These multimodal coexpression strategies are a prototype for the development of 'universal' vector systems, where direct localization and quantification of the PET marker gene reveals an indirect localization and quantification of the proportionally coexpressed therapeutic gene. 22 This
Molecular imaging of gene therapy for cancer K Shah et al allows, a noninvasive determination of the 'tissue-dose' of vector-mediated gene expression and, hence, the gene therapeutic capacity of the delivery system. Imaging transcriptional regulation of endogenous genes in living animals using noninvasive imaging techniques provides a clear perception of normal and cancer-related biological processes. Radiolabeled reporter probes and PET imaging can be translated into human studies in the near future. The endogenous expression of p53, a gene that affects several important biological processes, has been imaged in vivo with PET. A retroviral vector, Cis-p53/TK-GFP, was generated by placing the HSV-TK-GFP fusion gene 26 under control of an artificial cis-acting p53-specific enhancer element. ]FIAU-PET images and X-gal-stained tissue sections. These comparisons demonstrate the spatial relationship between HSV-1-TK-related radioactivity (arrow) and lacZ gene expression (right) in the same tumor region, indicating that noninvasive localization of any proportionally coexpressed gene is possible. In (b), indirect quantification of other biological properties of the hrR3 vector with the radiotracer assay used for imaging. Proliferating rat 9L gliosarcoma cells in culture were infected with hrR3 at a multiplicity of infection of 1.5 PFU/cell. Time-dependent changes of HSV-1-TK activity, viral yield and lacZ gene expression were quantified. Correlations demonstrate that the radiotracer assay is not only a direct measure for HSV-1-TK activity but serves also as indirect measure of viral propagation and proportionally coexpressed lacZ gene activity. All together these data form the basis for the noninvasive localization and quantification of any gene of interest, which is proportionally coexpressed with a PET marker gene (adapted from Jacobs et al 12 with permission). Tc introduced into an organism. These radionuclides emit a single photon. SPECT imaging involves the rotation of a photon detector array around the body to track the position and concentration of radionuclide distribution from multiple angles. SPECT has been used to follow the distribution of antibodies to the transmembrane receptor kinase, ERBB2, 28 herpes simplex virus 29 and receptor-binding molecules (Astatine-211). 30 SPECT has been used to image cell-surface-expressed receptors and transporters. The gene encoding the human somatostatin receptor type-2 has been used as a marker gene in combination with the specific marker receptor-binding compound [ 99m Tc]-P2045, which can be detected by gamma-camera and SPECT imaging. 31 The expression of a cell-surface receptor, human carcinoembryonic antigen (CEA), delivered via adenovirus vector into experimental subcutaneous human D54MG gliomas was noninvasively assessed by 131 I-labeled anti-CEA COL-1 monoclonal antibody. 32 This indicates that exogenously introduced cell-surface receptor expression can be imaged by SPECT; however, quantification of receptor expression at high levels might be confounded by saturation of intracellular processing or cell membrane sites.
SPECT can be used to image novel cell-surface expressed fusion proteins, which can be designed to bind radioisotopes that are currently in clinical use. 33 Recently Tc] MIBI SPECT is its ability to diagnose the presence of P-glycoprotein overexpression in vivo in order to evaluate potential drug resistance of tumors.
MRI and MRS
The fundamental principle underlying MRI is that unpaired nuclear spins (such as hydrogen atoms in water and organic compounds) align themselves when placed into a magnetic field. A temporary radiofrequency pulse is then given to change the alignment of the spins, and their return to baseline is recorded as a change in electromagnetic flux. MRI has the advantage of very high spatial resolution and the ability to measure more than one physiological parameter using different radiofrequency pulse sequences. Like most imaging modalities, MRI also uses injectable contrast agents which work by altering the local magnetic field in the tissue being examined. Paramagnetic metal cations, such as chelated gadolinium or dysprosium, or supramagnetic nanoparticles (magnetic particles with dimensions in the order of tens of nanometers that do not have magnetic properties outside the magnetic field) can be used as compartmental, targeted or smart probes within MRI. 36 Normal and abnormal tissues will respond differently to the slight magnetic field alteration, thus giving different signals, with these varied signals being transferred into images.
Imaging of gene expression using MRI may be achieved by two approaches: (1) imaging of introduced reporters or enzymes, which bind or metabolize paramagnetic substrates; or (2) imaging of a unique spectroscopic signature. 37 Imaging gene expression by the use of receptors expressed on the cell surface, for example the transferrin receptor can be achieved by endocytotic internalization of supraparamagnetic substances, such as monocrystalline iron-oxide nanoparticles (MION). 38 Tumor cells have a higher rate of endocytosis than normal cells and thus can be labeled selectively. 39 For 
example, the human transferrin receptor (TfR) is expressed at higher levels on a variety of tumor cell types and can be imaged using transferin (Tf) bound supramagnetic particles. 40 Further, a genetically engineered form of the human transferrin receptor (ETR), lacking the negative feed back mechanism that results in the downregulation of endogenous TfR expression, was expressed in 9L glioma tumors. 40 At 24 h after perfusion of supraparamagnetic Tf particles into tumor-bearing mice, ETR þ tumors in vivo showed considerably enhanced MR signal intensity as compared to the same tumors lacking the ETR. HSV-based amplicon vectors have also been used to deliver ETR as a reporter, the expression of which can be probed with a dextran crosslinked iron oxide (CLIO)Tf superparamagnetic nanoparticles, with ETR gene expression correlating with expression of therapeutic genes carried by the same amplicon. 41 Thus, MRI of ETR expression can serve as a surrogate for measuring therapeutic transgene expression.
Another way to monitor gene expression in vivo by MRI is to use biocatalysts to generate MR probes in situ. Several enzymatic systems have come forth based on single enzymes, such as tyrosinase 42 to catalyze the conversion of low-relaxivity substrates into high-relaxivity products. Tyrosinase, an enzyme normally involved in melanogenesis, 43 has a remarkably high metal-binding capacity (up to 35% by weight), particularly of iron, that results in the high signal intensity in melanomas on T1-weighted images. 44 Tyrosinase catalyzes two major reactions that occur primarily in lysosomes or premelanosomes: (a) the hydroxylation of L-tyrosine with the formation of L-DOPA (3,4-dehydroxy-L-phenylalanine); and (b) the subsequent oxidation of DOPA with the formation of DOPA quinone. Several COOH-terminally truncated mutant forms of tyrosinase were engineered, based on the hypothesis that in the absence of sorting signals, tyrosinase would not be sequestered exclusively in lysosomes/premelanosomes and tyrosinase-generated quinones could then cause toxicity to tumor cells. 34 The expression efficiency, enzyme activity, and toxicity of these mutant tyrosinases were compared in several transformed cell lines. The mutant tyrosinases were able to convert certain model prodrugs into cytotoxic agents with resultant cell death and antiproliferative effects. Thus, tyrosinase mutants can serve for both antitumor gene therapy, as well as imaging marker gene expression.
The use of novel MRI contrast agents that can indicate reporter gene expression for commonly used marker enzymes, like b-galactosidase, offer the promise of in vivo mapping of gene expression in transgenic animals. One approach is the use of paramagnetic chelates that have the capacity to change their magnetic properties upon enzymatic hydrolysis. 45 A paramagnetic galactopyranose chelator substrate for b-galactosidase has been developed based on the observation that the relaxivity of chelated gadolinium can be modulated by conjugating into b-galactose via a spacer. The removal of b-galactose from the paramagnetic conjugate by b-galactosidasemediated hydrolysis results in an increase in relaxivity by about 40%, which is detectable by MR imaging. This phenomenon has been used to image b-galactosidase activity in Xenopus laevis embryo. 45 MR spectroscopy (MRS) shares the same principle as MRI. In MRS, the signal obtained from a single element is further separated into its different chemical forms. It is thus possible to define a spectrum of nuclear magnetic resonance signals, in which the several chemical forms of an element give peaks in specific positions and thus offer the potential to measure gene expression. MRS has been used for quantitative noninvasive imaging of tumors. 46 Animals bearing tumors expressing the cDNA encoding for cytosine deaminase from yeast (yCD) were treated with nontoxic 5-fluorocytosine (5-FC) prodrug. The yCDcatalyzed conversion of 5-FC to the chemotherapeutic agent 5-fluorouracil (5-FU) was quantitated in vivo using 19 F MRS. This study demonstrated the local conversion of 5-FC to 5-FU, validating the concept of localized chemotherapy by enzyme prodrug activation. The ability of MRS to follow prodrug conversion dynamically and to distinguish between individual metabolites is a significant advantage over PET methods, which would require measurement of plasma metabolite levels.
Gemacitabine (dFdCyd) is a cytotoxic deoxycytidine (dCyd) analog that has demonstrated significant antitumor activity in a variety of human tumor models. 47, 48 dFdCyd is converted to an active metabolite by phosphorylation to a triphosphate derivative, dFdCTP, which is then incorporated into DNA. This reaction is catalyzed by a rate-limiting enzyme, deoxycytidine kinase (dCK). 19 F MRS has been recently used to detect increased incorporation of dFdCTP in human colon carcinoma xenografts in mice infected with a retroviral vector containing the dCK gene. 49 This finding has potential clinical relevance in dCK gene-directed therapy through enhancing cytotoxic effects of dFdCyd chemotherapy and allows use of 19 F MRS as a noninvasive tool to determine efficacy of prodrug conversion.
Recent advances in the development of magnetic nanoparticles and their use in cell tracking heralds high potential for MRI in the future. Magnetic nanoparticles have been used to track and recover as few as 100 cells after a specific population of cells was specifically labeled and followed using MRI. 50 Also, magnetic nanosensors have recently been developed with the capacity to detect specific DNA or mRNA sequences. 51 Following hybridization of supraparamagnetic nanoparticles bound to DNA to cellular nucleotide sequences, these probes exert sensitive and reversible effects on spin-spin relaxation of water protons.
Fluorescence imaging
Fluorescence imaging offers the possibility to image proteins and mammalian cells expressing them rapidly and inexpensively. The (GFP), a 27 kDa protein from jelly fish Aequorea victoria, fluoresces in green upon illumination with UV light. 52 GFP can be easily introduced into virtually any cell type using standard transduction methods and stable cell lines with continuous GFP expression can be produced. In addition, fusion of GFP with other proteins generates labeled proteins that can monitor specific cell compartments and dynamic processes in cells. 53 Spectral variants of GFP have also been produced using mutagenesis to alter sequences in the region of the chromophore. 54 This has resulted in the blue-shifted variant (BFP), a cyan-shifted variant (CFP) and a yellow-shifted variant (YFP), all with different emission wavelengths, thus allowing simultaneous monitoring of multiple proteins within the same cell or organism. The use of GFP fluorescence imaging has been employed in several cancer applications. For example, Molecular imaging of gene therapy for cancer K Shah et al human ovarian tumor cells were infected with a replication-deficient adenovirus vector encoding GFP, and the GFP-positive cells were imaged both in culture and in vivo by fluorescence stereomicroscopy in mice. 55 As discussed above, the functional coexpression of an engineered TK-GFP fusion protein was assessed in gliosarcoma, glioma and carcinoma cells. 26 This fusion protein served both as a screening marker for fluorescence microscopy and for fluorescence-activated cell sorting (FACS) and also as a therapeutic reporter rendering TK-GFP-expressing cells sensitive to ganciclovir.
Recently, strategies are being deviced to overcome the limitation of monitoring of fluorescent signals within organs in living animals. This limitation is due to the fact that GFP excitation and emission wavelengths, which fall in the range of 500 nm (ie, green light), have a very low tissue penetrance (1-2 mm) . One new strategy is the combination of fiber optic monitoring coupled with confocal microscopy that allows direct, rapid and sensitive visualization of fluorescent signals in brain, for example in glioblastoma cells infected with an adenovirus vector expressing GFP implanted into the rat hippocampus. 56 Although many strategies for visualization of GFP in vivo have been designed, in the majority of cases, GFP-expressing tumors must often be exposed surgically to visualize the reporter.
Intravital microscopy (IVM)
IVM is a powerful optical-imaging technique that allows continuous noninvasive monitoring of molecular and cellular processes in intact living tissue with 1-10 mm resolution. 57 IVM provides powerful insights into gene expression and function in tumors. The ability to monitor several parameters simultaneously with IVM has provided integrated insight into tumor responses to various therapies. This insight has led to new strategies for improving cancer detection and treatment. For example, it has been recently shown that blocking vascular endothelial growth factor (VEGF) or VEGF receptor 2 leads to a decrease in vessel diameter and vessel density (anatomical imaging) and a decrease in vascular permeability (functional imaging). [58] [59] [60] Intravital microscopy has been used to monitor the activity of the VEGF promoter in transgenic mice harboring enhanced GFP under control of this promoter. 61 When subcutaneous pancreatic tumors in SCID mice were injected directly with adenovirus vectors encoding the soluble form of the VEGF flt-1 receptor (Adsflt) or control vectors (AdLacZ), IVM revealed that AdLacZ-infected cells prompted strong tumor angiogenesis, whereas Adsflt-infected cells secreting a decoy receptor failed to exert such an effect. 62 IVM also revealed leukocyte rolling and increased adhesion within minutes in response to intravenously administered control adenovirus vector in the postsinusoidal venules of mouse liver indicating neutrophilmediated inflammation. 63 
NIRF reflectance imaging
Imaging in the near-infrared (NIR) spectrum (700-900 nm) maximizes tissue penetrance in addition to minimizing the autofluorescence from nontarget tissue. NIR fluorescence imaging relies on light with a defined bandwidth as a source of photons that encounter a fluorescent molecule (optical contrast agent). This fluorescent molecule then emits a signal with different spectral characteristics that can be resolved with an emission filter and captured with an ultrasensitive CCD camera.
1 Advances in NIRF imaging have been accelerated by the development of NIR fluorochromes coupled to quenching peptides that are activatable by specific proteases at the target site. 64 Studies with NIRF probes, both in culture and in vivo, have shown that the nonactivated probes have a very low background fluorescence and that protease activation of probes can increase the fluorescence over several hundred-fold 65 with probes detectable in the nanomolar range and with no apparent toxicity. 1 Autoquenched NIRF probes that become active after protease activation have been used in imaging tumors that have upregulated levels of certain proteases, like cathepsins. 66 Cathepsin B and cathepsin H protease activities have also been used to detect submillimeter-sized tumors using NIR fluorescent probes, 66 and cathepsin D-positive tumors 67 have been imaged in mouse models (Figure 3) . In another study, cathepsin B activity has been used as a biomarker to readily identify dysplastic adenomatous polyps, which contrasts particularly well against normal adjacent mucosa. 68 This detection technology can be adapted to endoscopy or tomographic optical imaging methods for screening of suspicious lesions and allows the potential for molecular profiling of protease activity in vivo.
A number of different matrix metalloproteinase (MMP) inhibitors, which act as cytostatic and antiangiogenic agents, are currently in clinical testing. One major hurdle in assessing the efficacy of such drugs has been the inability to detect or image antiproteinase activity directly and noninvasively in vivo. Recent developments allow NIRF-MMP substrates to be used as activatable NIRF reporter probes to monitor MMP activity in intact tumors. 69 These probes have the advantage of directly imaging MMP activity within hours after treatment with potent MMP inhibitors.
NIRF probes can also be designed as reporters to image specific proteases introduced into the tumor cells via gene transduction by viral vectors. We have recently developed a probe for HIV-1 protease (PR) for imaging of gene delivery to tumors in vivo and for concordant activation of therapeutic proteins. Human 
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Gli36 glioblastoma cells infected with an HSV amplicon vector expressing HIV-1PR showed specific fluorescence activation of this NIRF probe. 70 To determine whether the HIV-1PR could be used as a marker transgene for in vivo imaging, Gli36 gliomas in the lateral abdomen of nude mice were injected with HIV-1PR amplicon vector and 36 h later HIV-1PR-NIRF probe was administered intravenously. Subsequent NIRF imaging showed significantly higher (44-fold) signal from HIV-1PR amplicon-infected Gli36 tumors as compared to control vector-infected tumors 70 ( Figure 4a-d) . This study demonstrates that viral proteases delivered via viral vectors can be imaged in live animals and thus serve as a transgene marker in tumor therapy as well as in testing the efficacy of HIV-1 protease inhibitors in vivo.
Fluorescence-mediated tomography (FMT)
FMT is an advanced method for acquiring images of fluorescently labeled proteins and is the imaging method of choice for deeper targets. In this method, the subject is injected with a fluorescently labeled probe and exposed to continuous wave or pulsed light, and the emitted light is captured by detectors arranged in a spatially defined order in an imaging chamber. 36 A tomographic image is reconstituted after the data is mathematically processed. The feasibility of this technique using NIRF probes has been shown in the imaging and quantification of cathepsin B activity in gliosarcomas stereotactically implanted into brains of nude mice ( Figure 5 ), and also in associating protease levels with invasiveness in breast cancer xenografts. 71 FMT can be transferred to clinics to identify the earliest stages of a variety of cancers.
Bioluminescence imaging (BLI)
BLI exploits the emission of visible photons at specific wavelengths based on energy-dependent reactions catalyzed by luciferases. Luciferases comprise a family of photoproteins that emit detectable photons in the presence of oxygen and ATP during metabolism of substrates such as luciferin into oxyluciferin. Luciferase systems include, among others, the bacterial lux genes of terrestrial Photorhabdus luminescens and marine Vibrio harveyi bacteria, as well as eukaryotic luciferase luc and ruc genes from firefly species (Photinus) and the sea panzy (Renilla reniformis), respectively. The light from these enzyme reactions typically has very broad emission spectra that frequently extend beyond 600 nm, with the red components of the emission spectra being the most useful for imaging by virtue of easy transmission through tissues. The light output per cell can be determined in culture as an a priori assessment of the sensitivity of detecting a signal in a given animal model, although there is a marked reduction of signal in vivo.
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The predictions based on diffusion models and in vivo studies suggest that BLI can provide a sensitive and rapid assay for the study of oncogenesis and disease progression in living animal models.
Luciferase has been used for real-time, low-light imaging of gene expression in cell cultures, individual cells, whole organisms and transgenic organisms. Sensitive imaging systems have been built to detect and quantitate small numbers of cells or organisms expressing luciferase as a transgene. [73] [74] [75] BLI has been used to monitor tumor cell growth and regression, 76, 77 to visualize the kinetics of tumor cell clearance by chemotherapeutics 78 and to track gene expression. 36 Luciferase imaging has recently revealed gene transfer to tumors followed by a decrease in transgene expression with tumor cell death over time. A recombinant adenovirus coexpressing cytosine deaminase (CD) and firefly luciferase (Fluc) injected directly into the gliomas in mice showed significant expression of luciferase. 79 Further treatment of animals with 5-FC lead to a decrease in this imaging signal, presumably due to cell death. In parallel, diffusion-weighted MRI was used as a surrogate marker of tumor cell death. This multimodality approach thus provides noninvasive assessment of both the extent of gene delivery and the efficacy of the therapy.
The imaging of transgene expression under weak promoters may present difficulties due to the sensitivity of the current BLI methods. In a recent study, a novel method to enhance transcriptional activity using tissuespecific promoters was validated by employing a two-step transcriptional amplification (TSTA) system and bioluminescence imaging to amplify expression of Fluc and mutant herpes simplex virus type 1 TK (HSV1-sr39tk) in prostate cancer cells. 80 The first step involves tissuespecific expression of the GAL4-VP16 fusion protein and in the second step, GAL4-VP16 induction of target gene expression under the control of GAL4 response elements in a minimal promoter. Transcription of the reporter [83] [84] [85] [86] The ability to noninvasively track the engraftment, migration and proliferation of NPCs has significant clinical and research implications. Recently we have explored the macroscopic migratory capabilities of NPCs towards experimental tumors following implantation into nude mice at distant sites in the brain. 87 A line of NPCs stably expressing Fluc was either implanted into the brain parenchyma or administered via intraparenchymal and intraventricular injections into mice bearing intracranial gliomas. Using serial BLI, migration of NPCs implanted in the brain was observed across the corpus callosum towards the tumor, with movement first being detected at 1 week and maximal density within the tumor site observed at 2-3 weeks after implantation 87 ( Figure 6 ). These results confirm the histologically documented migratory capability of NPCs over considerable distances and their preferential accumulation in brain tumors upon CNS injection. 81 Other routes of injection also yielded NPCs in tumors, but to a lesser degree. These studies are relevant for potential clinical use because the route of administration of such cells could carry therapeutically active transgenes and their migratory capability can now be quantitated.
The ability to image two or more biological processes in a single animal can greatly increase the utility of luciferase imaging by offering the opportunity to distinguish the expression of two reporters biochemically. The luciferases from Renilla and firefly have different substrates, coelenterazine and D-luciferin, respectively, and can be imaged in tumors in the same living mouse with kinetics of light production being separable in time by separate injections of these two substrates. 88 Recently, dual bioluminescence imaging has been used to monitor gene delivery via a therapeutic vector and to follow the effects of the therapeutic protein TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) in gliomas. 70 Glioma cells stably expressing Fluc were implanted subcutaneously into nude mice and the tumor growth was monitored in vivo over time by luciferin administration and BLI. HSV amplicon vectors bearing the genes for TRAIL and Rluc were injected directly into these Fluc-positive gliomas allowing super imposition of gene delivery to the tumor by coelentrazine administration and BLI (Figure 7 ). This dual imaging approach has direct applications in studying the delivery of gene therapy vectors and simultaneously monitoring therapeutic effects in vivo.
Recently, activatable luciferase molecules, wherein the luciferase activity has been silenced by fusion with other proteins have been developed for imaging apoptosis. 89 Luciferase sequences were flanked at both termini with in-frame caspase-3 substrate sequences and estrogen receptor regulatory domains. Studies in culture with glioma cells expressing this fusion protein revealed attenuated luciferase activity that could be activated on induction of caspase-3. Furthermore, luciferase activation could be monitored in vivo when tumors generated from these cells were treated with TRAIL and underwent apoptosis. This ability to image caspase-3 activity noninvasively in vivo provides a unique tool for the Molecular imaging of gene therapy for cancer K Shah et al evaluation of therapeutic efficacy of experimental therapeutic agents, as well as for studies on the role of apoptosis in development and various disease processes. BLI in experimental animals has the advantage of being fast, relatively inexpensive, and broadly applicable in cancer research, and complements other developments in the molecular imaging field allowing real time information about complex pathophysiological processes in living organisms. This will lead to a better understanding of the underlying biology and thus result in improved disease prevention and treatment.
Conclusions and perspectives
There are numerous benefits of noninvasive monitoring (imaging) of transgene expression in gene therapy protocols. The ability to visualize transcriptional and translational regulation of endogenous and delivered gene expression, as well as specific intracellular proteinprotein interactions in experimental animals will provide the opportunity for new experimental venues for research in patients. In addition, monitoring the correlation between primary transduction and therapeutic efficiency of gene therapy vectors will be highly informative and can widely influence the development of safe and efficient uses of viral vectors in clinical settings.
